Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,095 USD | +0.02% |
|
+2.55% | +25.07% |
12/07 | UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating | MT |
11/07 | Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.07% | 12TCr | |
+19.86% | 13TCr | |
+24.86% | 2.79TCr | |
-16.93% | 2.1TCr | |
-14.87% | 1.69TCr | |
-13.51% | 1.62TCr | |
+10.88% | 1.48TCr | |
-47.10% | 1.48TCr | |
+53.48% | 1.41TCr | |
+144.93% | 1.26TCr |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-11-2021 05